LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.Adjusted earnings included an acquired in-process research and development (IPR&D) charge of $1.72 per share compared with 10 cents in...